Blog

SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.

As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.

Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.

Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).

To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox ^[1] . There is no effective drug for MPox at present.

Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon ^[1] .

Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.

We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.

The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.

The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.

Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses ^[2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.

To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.

Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.

NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

^[1] Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox therapeutics based on animal model data generated in animal infections by animal native orthpoxviruses. Tecovirimat failed in clinical trials of MPox. Brincidofovir caused sever drug-induced liver injury (DILI) in there of three patients given the drug in case studies, not in clinical trial.

^[2] It has been reported that highly pathogenic duck influenza viruses that lack or substantially lack HSPG binding ability do not cause significant pathology in other birds, nor in humans. They appear to use exclusively sialic acid-related receptors and yet have failed to infect other species. We believe these results require further investigation.

SOURCE: NanoViricides

View the original press release on ACCESS Newswire

By joining the RPOA community of leaders, LHH is taking a leading and active role in shaping the future of RPO and establishing the practice as a strategic engine for organizational agility.

NEW YORK CITY, NY / ACCESS Newswire / July 23, 2025 / LHH, a global integrated professional talent solutions provider and global business unit of the Adecco Group, today announced its Gold Membership with the Recruitment Process Outsourcing Association (RPOA). This move underscores LHH’s commitment to advancing the RPO industry and marks a significant step in LHH‘s strategic expansion within the RPO sector, with its full offering centralized by The Adecco Group under LHH earlier this year.

“Now that our RPO offering is fully integrated as LHH RPO, our partnership with RPOA is critical to ensure we are actively guiding the strategic evolution and new standard of RPO globally,” shared Serge Shine, Global Head of LHH RPO. “LHH is the only provider that combines flexible RPO solutions with development and career transition services, helping organizations solve talent challenges holistically. We help organizations think bigger than just filling jobs. By connecting hiring to their larger talent priorities, we make every recruitment decision count. This comprehensive approach empowers our clients to hire smarter and pivot faster.”

“That’s not the only thing that sets LHH RPO apart.” Adds Alex Ridder, LHH RPO Head of Client Partnerships: “Talent acquisition isn’t happening in isolation anymore, that’s why we designed LHH’s RPO offering to be highly adaptable. Whether it’s scaling recruitment quickly in competitive markets, integrating new hiring tech without disrupting teams, or building talent pipelines for hard-to-fill roles, we help people make work meaningful while helping to tackle the tough challenges together. Our approach combines innovation and human centricity, with exceptional care, to deliver results that matter.”

With 400+ experts across five continents, LHH RPO works with clients across various industries to develop and optimize their RPO strategies through a comprehensive and flexible suite of RPO solutions, backed by global reach and local knowledge, to help drive cost efficiency and transform organizations across the entire talent lifecycle.

Earlier this year, LHH RPO was named a ‘Major Contender’ in Everest Group’s 2025 PEAK Matrix® for Global RPO Services, a milestone moment and a reflection of the impact LHH brings in rethinking talent solutions.

“LHH joining the RPOA network supports our mission of fostering a collaborative community where RPO leaders can gather and share knowledge, transforming the future of the workforce collectively,” said Lamees Abourahma, RPOA CEO. “LHH RPO provides value to our members addressing the challenges and needs of the RPO ecosystem with unique perspectives.” She added, “We’re thrilled to recognize and support LHH’s RPO integration and market expansion and look forward to welcoming their experts to engage, learn and contribute to the evolution of the RPO industry. This is what the RPOA is all about, empowering leaders and advancing the profession.”

For more information on LHH RPO’s offerings, visit LHH’s Guide to Recruitment Process Outsourcing or contact LHH RPO.

###

About LHH

LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions.

LHH’s full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge.

We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology, and proprietary data analytics, LHH’s approach is crafted to align with business strategies and cultures, delivering powerful, sustainable, and measurable impact.

LHH has a team of over 12,000 professionals, across 60+ countries, and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide.

Recruitment. Development. Career Transition.
LHH. A beautiful working world.

To learn more about LHH, visit: lhh.com.

About RPOA

The Recruitment Process Outsourcing Association (RPOA) is a member-driven, mission-driven organization committed to advancing, elevating, and promoting recruitment process outsourcing as a strategic talent solution. We strive to nurture a collaborative community, create thought leadership, and educate the marketplace about recruitment process outsourcing. Learn more at https://www.rpoassociation.org/

Media Contacts
LHH Public Relations
PR@lhh.com

RPOA
Lamees Abourahma, CEO
lamees@rpoassociation.org

The Adecco Group’s RPO business was consolidated under LHH in January 2025.

SOURCE: LHH

View the original press release on ACCESS Newswire

NEW YORK, NY AND SINGAPORE / ACCESS Newswire / July 23, 2025 / trueGold Consortium Pty Ltd, a subsidiary of SMX (Security Matters) PLC (NASDAQ:SMX), is revolutionizing the gold industry with chemical marking technology that creates a fully traceable and verifiable supply chain-from mining to the marketplace and, ultimately, into recycling. The system adds an invisible marker at the mine-site, records every hand-off on a secure digital ledger, and allows instant verification at any point in the metal’s life. The result is unprecedented transparency, accountability, and the confidence for brands to meet stringent ethical-sourcing standards.

Gold has always carried emotional value; now with SMX technology, it can carry verifiable truth. The SMX technology captures the whole journey in the finished gold product itself, giving brands an authentic story to tell and consumers confidence in an ethically sourced supply chain.

Why an Embedded Memory with the Final Product Matters

At the gold mine and refinery, the SMX marker provides incontrovertible proof of sourcing, which can help streamline audits and regulatory filings. As the same gold moves through logistics providers, vaults, and workshops, every transfer can be both recorded digitally and verified tangibly, eliminating gaps and disputes in chain-of-custody documentation. When the metal reaches the retail brand, each finished piece would then carry a digital passport that can help substantiate ESG claims and differentiates collections in a crowded luxury market. Finally, the consumer can enjoy one-scan assurance of authenticity, recycled content, and ethical provenance-all encoded within the jewelry they wear.

Rising Consumer Demand

Independent studies show that more than 70 percent of shoppers are willing to pay a premium for products whose provenance is transparent and tamper-proof:

• IBM Institute for Business Value surveyed 19,000 consumers across 28 countries and found 71 % would pay up to 37 % more for goods with full transparency and traceability.

• PwC’s 2024 Voice of the Consumer Survey showed consumers globally willing to spend an average 9.7 % extra on sustainably sourced goods.

The Company believes that trueGold’s application of its marking technology to watches and jewelry positions it to deliver provenance-assured pieces to discerning customers.

Quality, Health & Safety Assured

Recent independent testing by Intertek under the AnchorCert Pro 2 protocol on an SMX-marked 18-karat red-gold ring confirmed compliance with jewelry-safety regulations in Europe, the United States and Canada.

The results show that SMX’s invisible marker remains chemically inert, non-toxic and undetectable in normal wear, without affecting the metal’s purity or skin compatibility. The ring satisfied all relevant EU REACH and RoHS limits, passed U.S. ASTM F2999-19 and National Stamping Act requirements, and met Canada’s Precious Metals Marking Regulations-evidence that robust traceability can coexist with the highest standards of consumer safety and product quality.

Sources & References

1. IBM Institute for Business Value, “Purpose and Provenance Drive Bigger Profits for Consumer Goods,” 2020 – 71 % of consumers would pay a premium for products offering full transparency and traceability.

2. PwC, “2024 Voice of the Consumer Survey,” 2024 – Consumers are willing to spend an average 9.7 % more on sustainably sourced goods.

3. Securing Industry, “SMX’s Subsidiary trueGold Extends its Commercial Activity to Watches and Jewelry,” 2023 – Announces expansion of trueGold’s molecular-marking technology to finished luxury products.

4. London Bullion Market Association (LBMA), “Gold Bar Security Features,” market-standards page, accessed July 2025 – Describes accredited security features that establish a bar passport and link to the Gold Bar Integrity database

SMX GENERAL ENQUIRIES	Follow us through our social channel @secmattersltd
E: info@securitymattersltd.com	@smx.tech

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

LAS VEGAS, NV / ACCESS Newswire / July 23, 2025 / Adapti, Inc. (OTC:ADTI) announced that with the completion of acquisition of the Ballengee Group, Jeff Campbell, a seasoned executive with deep experience in both social media and sports, was appointed to serve as Executive Chairman of the Board of Directors of the company. Prior to his appointment to the Board, Mr. Campbell acted as a consultant to Adapti.

From 2019 to 2023, Mr. Campbell previously served as chief revenue officer of Fitlab, a private fitness and sports lifestyle company with an integrated fitness platform. During Mr. Campbell’s tenure, he helped grow the fitness platform to $100mm in annual recurring revenues. Prior to that, Mr. Campbell served as CEO of Geographic Farming, a digital media agency, where oversaw growth of annual revenue by 400% in under 2 years, before the agency was sold. Mr. Campbell also previously served as President of UFC Fit and early in his career, worked for sports agent, Leigh Steinberg.

“I’m honored to join Adapti’s Board as Executive Chairman,” said Jeff Campbell. “The convergence of sports management, social media strategy, and adaptive AI-powered influencer technology represents the industry’s next frontier. I look forward to guiding Adapti on the ground floor of this evolution and helping the company achieve its full potential.”

“To attract a seasoned executive and visionary like Jeff to serve as our Executive Chairman is a tremendous milestone for Adapti,” said Adam Nicosia, CEO of Adapti. “Jeff’s proven track record as a thought leader in media strategy-culminating in multiple successful exits-makes him uniquely qualified to help steer our Board and drive our growth strategy forward. His expertise and vision will be instrumental as we scale our integrated platform for the sports world and deliver value to our clients.”

About Adapti, Inc. (OTC: ADTI)

Adapti, Inc. leverages advanced AI technology to match products and brands with optimal influencers, using proprietary data analytics to drive superior marketing results. Adapti aims to build a global platform where data is an asset, efficiently paired with high-impact influencers.

In July 2025, Adapti acquired the Ballengee Group, a full-service sports agency representing Major League Baseball athletes. The Ballengee Group assists its clients with contract negotiations, marketing deals, public relations, and strategic partnerships. The Ballengee Group has guided world champions and global icons throughout their careers.

Adapti plans to roll out a suite of integrated services that blend traditional contract negotiation and endorsement deals with dynamic social media campaigns, which we anticipate will be powered by AdaptAI’s proprietary “data fingerprint” technology that the company is developing. This technology will utilize Large Language Models to quickly optimize and adapt to changes in the ever-evolving marketing landscape. This holistic approach is being designed to maximize engagement, drive higher ROI for brand partners, and ensure athletes capture every opportunity to grow their platforms.

For more information, please visit our website: http://adapti.io. The information contained on our website is not incorporated by reference into this press release, and we disclaim any liability for such information.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Adapti, Inc. generally identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. Adapti based these forward-looking statements largely on their then-current expectations and projections about future events and financial trends as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Adapti’s control. Adapti’s actual results (including those of Ballengee post-acquisition) could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the ability to integrate the business operations of Ballengee with that of Adapti, (ii) the ability of Adapti to timely make the necessary filings with the SEC related to the acquisition of Ballengee, and (iii) those risks detailed in Adapti’s reports filed with the SEC, as well as other documents that may be filed by Adapti from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Additional risks and uncertainties can be found in the Company’s recent annual and quarterly reports, filed with the SEC or other filings that are filed with the SEC thereafter. Adapti cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Adapti undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

Investors Contact:

Phone: 214-301-3745
Email: investorrelations@adapti.io

SOURCE: Adapti, Inc.

View the original press release on ACCESS Newswire

SOLO™’s Non-Proliferation Approach Aligns with U.S. NRC’s Proposed Licensing Framework Criteria for Low Risk, Proliferation-Resistant Micro Modular Reactors

NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / July 23, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (NASDAQ:GSRT), a publicly traded special purpose acquisition company, today issued the following statement in support of the U.S. Nuclear Regulatory Commission’s (“NRC”) long-term vision for micro-modular reactor licensing, following the NRC’s public meetings on July 17-18, 2025:

“We are encouraged by the NRC’s recent public dialogue and their proposed rulemaking regarding future streamlined licensing for micro-modular and other low risk reactors. In particular, we support the NRC’s introduction of limits on the type and quantity of proliferation materials – or ‘Special Nuclear Materials’ (SNM) such as uranium or plutonium – in its proposed fundamental entry criteria, which further validates and aligns with SOLO^TM‘s Safeguards by Design approach.

In Picture: A rendering of the SOLO™ reactor seamlessly integrated within a commercial real estate setting.

From the earliest stages of development in 2018, we conceived our micro-modular reactor with a clear global mission: to deliver a safe, low risk, and non-proliferant nuclear energy solution suitable for deployment in diverse environments around the world. Recognizing the unique challenges associated with the use of SNM, we emphasized proliferation resistance not as an afterthought, but as a core design principle.

Our reactor has been embedded with safeguards which aim to limit unauthorized access, diversion, or repurposing of fissile materials and align with guidance from the International Atomic Energy Agency and Department of Energy.

SOLO^TM‘s compact, sealed core design, limits SNM while incorporating a real-time core measurement to prevent the misuse of these materials. Additionally, our decision to use standard Low Enriched Uranium fuel supports international non-proliferation objectives while leveraging existing fuel infrastructure and licensing precedents.

We commend the NRC for its transparent, inclusive approach to rulemaking and look forward to participating in the formal comment process. Terra Innovatum remains committed to working with domestic and international stakeholders to advance the responsible deployment of micro-modular reactors – and to ensuring that designs like SOLO^TM continue to lead the way.”

ABOUT TERRA INNOVATUM & SOLO^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

CONTACTS

Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.terrainnovatum.com

Nicholas Hresko-Staab
Vice President
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

IMPORTANT INFORMATION FOR SHAREHOLDERS

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

PARTICIPANTS IN THE SOLICITATION

Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination,

which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to

update or revise any forward-looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

SOURCE: TERRA INNOVATUM SRL

View the original press release on ACCESS Newswire

Seniors are often surprised by taxes on mandatory withdrawals – Clear Start Tax explains how RMDs can increase IRS balances in retirement.

IRVINE, CA / ACCESS Newswire / July 23, 2025 / Many retirees assume their tax worries end with their final paycheck, but Required Minimum Distributions (RMDs) are catching them off guard. According to Clear Start Tax, mandatory withdrawals from retirement accounts like 401(k)s and traditional IRAs are pushing thousands of seniors into higher tax brackets – and in many cases, deeper IRS debt.

“RMDs aren’t optional, and neither are the taxes they create,” said the Head of Client Solutions at Clear Start Tax. “We see clients who’ve paid off their homes, receive Social Security, and still end up owing thousands to the IRS just because they didn’t plan for the tax hit.”

How RMDs Can Trigger IRS Debt

Once a taxpayer turns 73 (as of 2025), the IRS requires them to begin withdrawing a calculated amount each year from qualified retirement accounts. These distributions are taxed as ordinary income, even if the funds are not spent.

Clear Start Tax outlines several ways RMDs can create or increase back taxes:

• Unexpected Withholding Gaps – Many custodians don’t withhold enough to cover the tax burden.

• Combined Income Penalties – RMDs added to Social Security and pensions can push retirees into higher tax brackets.

• Loss of Tax Credits – Increased income can disqualify seniors from deductions, credits, or affordable health plans.

• Missed Payments – Seniors on fixed incomes may not make estimated tax payments, causing interest and penalties to build.

“RMDs aren’t just income – they can tip the scales, especially when combined with unfiled returns or prior IRS debt,” added the Head of Client Solutions. “And since they’re required by law, you can’t just opt out.”

Why Retirees Often Miss the Warning Signs

Clear Start Tax notes that many seniors don’t realize their tax situation has changed. Without a W-2 or employer, there’s often no system in place for regular withholding, and no alert until a CP14 notice or lien arrives.

Additionally, seniors withdrawing from multiple accounts may fail to track their total taxable income. A small oversight can lead to large consequences.

What Seniors Can Do to Avoid RMD-Related Debt

Many retirees aren’t aware that Required Minimum Distributions (RMDs) are fully taxable, and skipping tax planning can lead to debt quickly. Clear Start Tax urges seniors to treat RMDs like any other income source and take proactive steps before tax time.

Clear Start Tax recommends:

• Review all retirement account distributions annually

• Adjust withholdings to better match tax liability

• Use IRS Form 1040-ES for quarterly estimated payments

• Recalculate tax strategy each year based on age, income, and filing status

• File missing returns before enforcement escalates

Fresh Start Program Offers Relief for Retirees

If tax debt has already built up – whether from unplanned RMD taxes or previous underpayment – retirees may still have viable relief options. Clear Start Tax helps seniors use IRS Fresh Start programs to resolve debt without jeopardizing essential income or retirement assets.

Clear Start Tax helps qualifying retirees:

• Apply for payment plans based on current income and expenses

• Submit Offers in Compromise to reduce the total amount owed

• Request penalty abatement for first-time or hardship-related cases

• Regain filing compliance to avoid enforcement actions or levies

• Protect Social Security income from garnishment, where applicable

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel’s financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion.

Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel’s mission.

“Avel eCare is transforming how healthcare is delivered across the country,” said Lenhardt. “It’s an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.”

This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas.

The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel’s leadership includes:

• Doug Duskin – Chief Executive Officer

• Don Yish – Chief Revenue Officer

• Jay Weems – Chief Operations Officer

• Kelly Rhone, MD – Chief Medical Officer

• Robert Spurlock – Chief Information Officer

About Avel eCare
Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire

March journal release details faster recovery, lower risk, and real-time patient input.

TAMPA, FL / ACCESS Newswire / July 23, 2025 / What if a woman could downsize and reshape her breasts without a single breath of general anesthesia? A newly published video article in Plastic & Reconstructive Surgery Global Open (March 21, 2025) documents exactly that: a fully conscious, comfortably numb breast-reduction technique created by Tampa plastic surgeon Meegan Gruber, MD, PhD.

Co-authored with Canadian educator Donald H. Lalonde, MD, the paper, “Wide Awake Breast Reduction,” combines tumescent liposuction with immediate skin and gland excision, all under local anesthesia. Over seven years and dozens of cases, Dr. Gruber reports zero conversions to general anesthesia, no drains, and next-day pain scores averaging 1-2 of 10 on non opioid medication.

“Patients sit up mid-procedure so we can fine-tune nipple position and symmetry in real time,” Dr. Gruber said. “They walk out clear-headed, avoid nausea, and resume light activity within 48 hours, outcomes impossible with traditional intubation.”

Why It Matters

• Safety first – Eliminates airway manipulation, aspiration risk, malignant hyperthermia, and most thromboembolic events.

• Economic win – Fewer staff, no post-anesthesia unit, reduced pharmaceutical costs.

• Broader eligibility – Opens breast surgery to patients who cannot tolerate general anesthesia or live in regions lacking full OR infrastructure.

• Patient empowerment – Awake patients help gauge gravity effects, shift positions for comfort, and leave surgery feeling in control of their bodies.

The publication arrives as consumer interest in minimal-anesthesia procedures explodes. Industry forecasts predict a 35 percent jump in awake cosmetic surgeries nationwide by 2028, driven by shorter downtime and rising skepticism over heavy sedation.

How the Technique Works

• Tumescent infiltration – Dilute lidocaine-epinephrine-ropivacaine solution numbs tissue and minimizes bleeding.

• Liposuction first – Rapid, nearly bloodless removal of lateral breast fat creates a clean dissection plane.

• Skin & gland excision – With the patient upright and alert, redundant skin and dense tissue are trimmed to target volume.

• No drains, no twilight drugs – Patients eat a light breakfast, take oral Tylenol and antibiotics, and remain fully conscious throughout.

Seven years of data show no need for postoperative narcotics in most cases and no unplanned hospital transfers. Contraindications are limited to extreme anxiety, extensive scar tissue, or cardiac arrhythmias aggravated by epinephrine.

A Patient’s Voice
Lisa M., 37, who lost 80 pounds before surgery, calls the experience “liberating”: “I chatted with Dr. Gruber, saw my new shape before closure, and best of all never felt groggy. I was back to work in three days.”

The Bigger Picture
With invitations to present at next month’s American Society of Plastic Surgeons, and Korea’s KPS meeting, Dr. Gruber aims to train colleagues worldwide. “Wide-awake breast reduction proves we can make surgery safer, simpler, and more patient centric,” she said. “It’s the future and the future is wide awake.”

About Gruber Plastic Surgery

Gruber Plastic Surgery, located in Tampa, FL, is led by Dr. Meegan Gruber, MD Ph.D., a board-certified plastic surgeon renowned for her pioneering work in awake surgery. Dr. Gruber, also the star of “Awake Surgery,” which you can stream today on TLC GO, HBO MAX, Hulu, Discovery+, and other streaming platforms, integrates advanced techniques and cutting-edge technology to deliver safe, comfortable, and natural-looking results with minimized recovery time. Specializing in awake surgeries, the clinic offers a range of state-of-the-art procedures. Dr. Gruber is committed to innovation and education, ensuring precision and safety in every treatment, while enhancing patient confidence through individualized care and surgical expertise.

SOURCE: Gruber Plastic Surgery

Related Images

View the original press release on ACCESS Newswire

La Dolfina/Scone Captures the Title Over Kazak, 9-8, in Front of Record Crowd

WEST PALM BEACH, FLA./MIDHURST, U.K. / ACCESS Newswire / July 23, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), served as the Official Apparel Partner of the 2025 British Open Polo Championship for the Cowdray Gold Cup, now in its fifth consecutive year of partnership with Cowdray Park Polo Club. For the first time, USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand, and its media subsidiary, Global Polo Entertainment (GPE), will broadcast the Cowdray Gold Cup on ESPN, bringing high-goal British polo to a global sports audience. Check your local listings for airtimes.

The 2025 British Open Polo Championship for the Cowdray Gold Cup was hosted at the historic Cowdray Park Polo Club from June 24 to July 20, with over 35,000 sports fans attending the semi-finals and finals. The prestigious tournament concluded with a thrilling final match as La Dolfina/Scone defeated Kazak with a score of 9-8 in front of over 15,000 fans. Making history, La Dolfina/Scone became the first team to win the British Open Polo Championship for the Cowdray Gold Cup as a father-daughter duo, with legendary player Adolfo Cambiaso and his daughter, Mia Cambiaso. La Dolfina/Scone’s game started early with a dominant 3-0 first chukker, maintaining control through sharp teamwork and standout defensive plays from Mia Cambiaso despite a spirited push from Kazak and key goals from Nico Pieres. U.S. Polo Assn. had the honor of presenting the Most Valuable Player Award to Mia Cambiaso from La Dolfina/Scone, who delivered an outstanding performance throughout the tournament.

U.S. Polo Assn. provided co-branded apparel for all on-site staff and brought immersive activations for event attendees. In collaboration with Brand Machine Group (BMG), U.S. Polo Assn.’s brand partner in the U.K., the brand hosted ticket sweepstakes, divot stomp prizes, cap giveaways, shopping vouchers, and also offered exclusive products sold on-site at a U.S. Polo Assn. pop-up merchandise shop. The global sports brand also donated to Cowdray Park Polo Club’s designated charity, Midhurst Palliative Care, accepted by Dr. Alex MacCallum, Chair of Trustees representing Midhurst Palliative Care.

“U.S. Polo Assn. is proud to support one of the top tournaments in the world and help bring the excitement of the 2025 British Open Polo Championship for the Cowdray Gold Cup to millions of viewers through ESPN for the first time,” said J. Michael Prince, President and CEO of USPA Global, which manages and oversees the multi-billion-dollar U.S. Polo Assn. brand. “This broadcast marks a powerful moment for the sport of polo and aligns with our long-term commitment to increasing access and exposure of the sport and our global sports brand in the U.K., one of our fastest-growing markets, around the globe.”

Sports fans enjoyed watching one of the highest levels of polo competition while experiencing the English charm of Cowdray Park Polo Club. The British Open Polo Championship for the Cowdray Gold Cup is widely regarded as one of the top tournaments in the world, alongside the U.S. Open Polo Championship®, the Argentine Open Polo Championship, the USPA Gold Cup®, and the Queens Cup. The event’s high-goal players included some of the top names in the sport of polo, such as Polo Hall of Famer Adolfo Cambiaso, as well as Poroto and Mia Cambiaso, Facundo and Nico Pieres, Mark Tomlison, Tomas Beresford, James Harper, Hugo Taylor, Camilo Castagnola, Hazel Jackson, and Hilario Ulloa, to name a few.

“In partnership with U.S. Polo Assn., we continue to build authentic connections while elevating the visibility of the iconic Cowdray Park Polo Club on a global scale to sports fans and consumers,” said Boo Jalil, CEO of Brand Machine Group, the U.K., Australian/New Zealand, and Polish partner for the U.S. Polo Assn. brand. “Bringing this prestigious tournament to ESPN viewers worldwide marks a major milestone not only for English polo but for the sport as a whole.”

First played in 1956 on the illustrious Cowdray Estate, boasting 16,500 acres, the Cowdray Gold Cup remains one of the most prestigious high-goal awards in the United Kingdom and globally today. Cowdray Park is recognized as the ‘Home of English Polo,’ with its first competitive polo tournament dating back to 1910. Located in the heart of England, Cowdray Park prides itself on its strong heritage of sporting excellence, where top polo players from around the world compete and are part of its history and tradition.

“Cowdray Park Polo Club is thrilled to have U.S. Polo Assn. as a valued and long-standing partner of the Gold Cup Competition,” said Jonathan Russell, CEO of Cowdray Park Polo Club. “The support of U.S. Polo Assn. as the Official Apparel Partner in the top tournament in the U.K. elevates the tournament experience and helps position the Cowdray Gold Cup on the world stage with its first-ever broadcast on ESPN.”

Photo Credit: Margarita Crotto (@margarita.crotto)

Content Credit: @pololineok

About U.S. Polo Assn. and USPA Global

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.

For more information, visit uspoloassnglobal.com and follow @uspoloassn.

USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary, Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.

About Brand Machine Group (BMG)

BMG is an international leader in fashion innovation, which has established itself as a vertical manufacturer and global licensing specialist with over four decades of industry experience. Partnering with recognized market leaders, BMG manages a seamless and collaborative process of designing, manufacturing, and delivering quality products while championing the DNA of a diverse portfolio of brands, spanning fashion, sports, outdoor, and homeware, including adult fashion, kidswear, and accessories.

BMG’s portfolio of brands includes U.S. Polo Assn. Penfield, New Balance Kids, Duchamp, Jack Wills, Flyers American Born, Lee Kids, Peckham Rye, Wrangler Kids, Juicy Couture. BMG reaffirms its commitment to upholding sustainable and ethical business practices by ensuring full transparency throughout its global supply chain, aligning with the ETI Base Code.

Visit uspoloassn.co.uk, brandmachinegroup.com, and follow @brandmachinegroup. For appointments, contact sales@brandmachinegroup.com.

About Cowdray Park Polo Club

Cowdray Park Polo Club is often described as the Jewel in the Crown of Cowdray. For the last century, Cowdray Park has been at the forefront of professional polo in the U.K. and internationally. Competitive polo has been played at Cowdray since 1910, when it was founded as a small country club by the Pearson family, whose passion for the sport has been unwavering. Cowdray hosts the internationally famous British Open Polo Championship for the Cowdray Gold Cup, and polo teams from around the world flock to Cowdray to participate. The Gold Cup is one of the most important events on the British social calendar and attracts the single largest polo audience in the United Kingdom.

For more information about polo at Cowdray, please visit www.cowdraypolo.co.uk.

###

Contact Information

Stacey Kovalsky
VP, Global PR & Communications
skovalsky@uspagl.com
+001.561.790.8036

Shannon Stilson
VP, Sports Marketing and Media
sstilson@uspagl.com
+001.561.227.6994

Gina Digregorio
Head of Marketing
gina.digregorio@brandmachinegroup.com
+44 (0) 7741 635 984

SOURCE: U.S. Polo Assn.

Related Images

View the original press release on ACCESS Newswire

Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio

SOUTHLAKE, TX / ACCESS Newswire / July 23, 2025 / Gore Range Capital (GRC) announced today that Waldencast plc (Nasdaq:WALD) has agreed to acquire Novaestiq Corp. (Novaestiq), one of GRC’s Fund II portfolio companies. Novaestiq, a joint-venture with Croma-Pharma GmbH (Croma), is developing a series of breakthrough injectable hyaluronic acid gels for the US market, including Saypha^® ChIQ™ and Saypha^® MagIQ™. Waldencast will launch this injectable line under the renowned Obagi Medical brand, recognized for its holistic, science-driven approach where potent skincare and professional procedures work in tandem to achieve and maintain optimal skin health and a youthful appearance.

This transaction marks a major milestone for Gore Range Capital and underscores the growing demand for high-quality skin health solutions. Leveraging Obagi Medical’s global reputation and the combined expertise of Novaestiq and Waldencast, the introduction of these new products is set to redefine the aesthetic skincare experience, offering patients targeted solutions backed by robust science and dermatological research.

“Our partnership with Croma was rooted in a shared commitment to scientific rigor, patient safety, and innovation in aesthetic medicine. With Waldencast and Obagi Medical now leading the next chapter, we are delighted that Saypha^® injectables will be made available to US physicians and patients, defining the next generation in integrated aesthetic and skincare solutions,” said Humberto C. Antunes, Partner at GRC.

Saypha^®,¹ currently undergoing the FDA approval process, is distinguished by the proprietary technology delivering advanced hyaluronic acid treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. The technology powers a portfolio of clinically proven products that lead in multiple performance categories including high HA content at injection, ideal gel distribution, and consistent injection force and behavior. Saypha^®, a product of Croma, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced. This global reach and deep market insight allow for the delivery of trusted, personalized care to patients and professionals worldwide.

“We are thrilled to see Novaestiq join forces with Waldencast, a move that amplifies our shared commitment to advancing aesthetic medicine. The introduction of Saypha^® ChIQ and MagIQ to the U.S. market under the Obagi Medical brand marks a significant step in delivering innovative, science-driven skincare solutions to patients worldwide,” Andreas Prinz, CEO of Croma.

“From a bold idea to a significant exit, Novaestiq’s journey reflects the power of a great team, focus, innovation, and the right partners,” said Miles Harrison, CEO & Co-Founder of Novaestiq. “The combination of Saypha^® with the Obagi Medical brand creates a category-defining platform in aesthetics, and I am deeply grateful to our partners for believing in our team and vision from day one.” Saypha^®‘s core pivotal studies are more than twice the size of typical nasolabial fold and midface trials and include the highest representation of Fitzpatrick Skin Types I, V, and VI, underscoring Obagi Medical’s mission to provide elective science-backed solutions for all skin types and tones.

“Novaestiq stands as a testament to our strategy of building high-quality assets through deep domain expertise and collaborative partnership. This transaction reflects our ability to identify innovations that advance clinical outcomes and to structure them for long term value creation,” commented Ethan Rigel, Managing Partner of GRC.

Waldencast has agreed to acquire Novaestiq in exchange for a combination of upfront cash, royalties in perpetuity based on net sales, and the contingent issuance of Waldencast class A shares (up to 9.8 million shares, equal to approximately 7% of Waldencast’s fully diluted class A shares) on the achievement of certain milestones, including the receipt of the FDA
approval and sales of the Saypha^® fillers. The terms of the transaction will be detailed in a Form 6-K that Waldencast will file with the U.S. Securities and Exchange Commission following this press release.

About Waldencast

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com/.

About Obagi Medical

Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm^® System, Obagi products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, ²Obagi empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand’s website: https://www.obaji.com/.

About Gore Range Capital

GRC is a committed investor in innovation and excellence in skin health. GRC continues to invest in impactful medical solutions that offer transformative results for physicians, patients and consumers. Learn more at: https://www.gorerangecapital.com/.

¹Saypha^® products are not approved medical devices, and each product has a premarket approval (PMA) application under review by the FDA. ²Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.).

Contact:

Chidi Nwankpa
Principal, Gore Range Capital
chidi@gorerangecapital.com
https://www.gorerangecapital.com/.

SOURCE: Gore Range Capital

View the original press release on ACCESS Newswire